Nagy J A, Brown L F, Senger D R, Lanir N, Van de Water L, Dvorak A M, Dvorak H F
Department of Pathology, Beth Israel Hospital, Boston, MA 02215.
Biochim Biophys Acta. 1989 Feb;948(3):305-26. doi: 10.1016/0304-419x(89)90004-8.
Tumor stroma formation results from the interaction of tumor cells and their products with the host and certain of its normal defense mechanisms, particularly the clotting and fibrinolytic systems. It is a process in which tumor cells render local venules and veins hyperpermeable with the result that fibrinogen and other proteins extravasate and clot, forming an extravascular crosslinked fibrin gel. Coagulation is mediated by an interaction between extravasated plasma clotting factors and tumor-associated and perhaps other tissue procoagulants. Parallel activation of the fibrinolytic system leads to substantial fibrin turnover, but fibrin nonetheless accumulates in amounts, variable from tumor to tumor, that are sufficient to provide a provisional stroma. This provisional stroma imposes on tumor cells a structure that persists even as tumor cells multiply and as the fibrin provisional stroma is replaced by mature connective tissue. The provisional fibrin stroma also serves to regulate the influx of macrophages, and perhaps other inflammatory cells, but at the same time, and in ways that are not fully understood, facilitates the inward migration of new blood vessels and fibroblasts, integral components of mature tumor stroma. Ascites tumors differ from solid tumors in that fibrin gel is not ordinarily deposited in body cavities and, as a result, there is no provisional stroma to impose an initial structure. Tumor stroma generation resembles the process of wound healing in many respects. However, it differs in the mechanism of its initiation, and in the apparent lack of a role for platelets. It also differs fundamentally in that invading tumor cells continually render new vessels hyperpermeable to plasma, thus perpetuating the cycle of extravascular fibrin deposition. In this sense, tumors behave as wounds that do not heal. Largely neglected in this review has been discussion of the numerous cytokines, mitogens, and growth factors that are widely believed to play important roles in tumor angiogenesis and wound healing; i.e., PDGF, FGF, EGF, TGF alpha, TGF beta, TNF, interferons, etc. This omission has been intentional, and for two reasons. First, these cytokines have already received considerable attention [100,123-128]. Second, it is not yet clear how closely the actions of these molecules, as described in vitro, relate to their functions in vivo. At present we are deluged with a surfeit of factors that have the capacity to induce new blood vessel formation in angiogenesis assays; these factors include not only peptides but lipids and even ions [126,129-131].(ABSTRACT TRUNCATED AT 400 WORDS)
肿瘤基质的形成源于肿瘤细胞及其产物与宿主及其某些正常防御机制的相互作用,尤其是凝血和纤维蛋白溶解系统。这是一个肿瘤细胞使局部小静脉和静脉通透性增加的过程,结果纤维蛋白原和其他蛋白质渗出并凝结,形成血管外交联纤维蛋白凝胶。凝血由渗出的血浆凝血因子与肿瘤相关以及可能的其他组织促凝剂之间的相互作用介导。纤维蛋白溶解系统的平行激活导致大量纤维蛋白周转,但纤维蛋白仍会以不同肿瘤而异的量积累,足以提供一个临时基质。这个临时基质赋予肿瘤细胞一种结构,即使肿瘤细胞增殖且纤维蛋白临时基质被成熟结缔组织取代,该结构依然存在。临时纤维蛋白基质还用于调节巨噬细胞以及可能的其他炎性细胞的流入,但与此同时,以尚未完全了解的方式促进新血管和成纤维细胞的向内迁移,它们是成熟肿瘤基质的组成部分。腹水肿瘤与实体肿瘤的不同之处在于,纤维蛋白凝胶通常不会沉积在体腔中,因此不存在施加初始结构的临时基质。肿瘤基质的产生在许多方面类似于伤口愈合过程。然而,其起始机制不同,且血小板似乎不起作用。它在根本上也有所不同,因为侵袭性肿瘤细胞不断使新血管对血浆具有高通透性,从而使血管外纤维蛋白沉积循环持续存在。从这个意义上说,肿瘤表现为不愈合的伤口。在本综述中很大程度上被忽视的是对众多细胞因子、有丝分裂原和生长因子的讨论,人们普遍认为它们在肿瘤血管生成和伤口愈合中起重要作用;即血小板衍生生长因子(PDGF)、成纤维细胞生长因子(FGF)、表皮生长因子(EGF)、转化生长因子α(TGFα)、转化生长因子β(TGFβ)、肿瘤坏死因子(TNF)、干扰素等。这种省略是有意的,原因有两个。首先,这些细胞因子已经受到了相当多的关注[100,123 - 128]。其次,目前尚不清楚这些分子在体外描述的作用与其在体内的功能有多密切的关系。目前,我们被大量能够在血管生成试验中诱导新血管形成的因子淹没;这些因子不仅包括肽,还包括脂质甚至离子[126,129 - 131]。(摘要截取自400字)